

Fig.S1 Molecular structures of template and other analogues.




Fig.S2 The selective adsorption capacity of MCNTs@TSTO-MIPs and MCNTs@TSTO-NIPs to TSTO, PROG, MTSTO, and TSTOP in the mixture solution.




Fig.S3 The reusability of MCNTs@TSTO-MIPs and MCNTs@NIPs towards TSTO.

Table S1

Recoveries of MCNTs@TSTO-MIPs absorbing TSTO for spiked LNCaP cell samples. (n=5)

LNCaP cell	TSTO					
	1.0 ng mL ⁻¹		5.0 ng mL ⁻¹		50.0 ng mL ⁻¹	
	Recovery (%)	RSD (%)	Recovery (%)	RSD (%)	Recovery (%)	RSD (%)
Intra-day	102.1	4.7	99.8	3.9	98.7	2.3
Inter-day	103.2	5.1	100.7	4.8	99.3	3.4






Fig. S4 Chromatograms of the human prostate cancer LNCaP cell spiked with TSTO at the concentration of 5.0 ng mL⁻¹ (A), elution of absorbed MCNTs@TSTO-MIPs (B), and TSTO standard sample (C).




Fig. S5 The inhibitory effects of different amounts of MCNTs@TSTO-MIPs and different incubation times on the proliferation of LNCaP cells.




Fig. S6 The flow cytometry of control (A), 10 (B), 20 (C), and 40 (D) $\mu\text{g mL}^{-1}$ of MCNTs@TSTO-MIPs for 48 h.